Background: Head and neck squamous cell carcinoma (HNSCC) represents a common cancer worldwide. Past therapeutic advances have not significantly improved HNSCC prognosis. Therefore, it is necessary to further stratify HNSCC, especially with recent advances in tumor immunology. Methods: Tissue microarrays were assembled from tumor tissue samples and were complemented with comprehensive clinicopathological data of n = 419 patients. H&E whole slides from resection specimen (n = 289) were categorized according to their immune cell infiltrate as "hot," "cold," or "excluded." Results: Investigating tumor immune cell patterns, we found significant differences in survival rates. Immunologic "hot" and "excluded" HNSCCs are associated with better overall survival than "cold" HNSCC patients (p < 0.05). Interestingly, the percentage of all three patterns is nearly identical in p16 positive and negative HNSCCs. Conclusions: Using a plain histological H&E approach to categorize HNSCC as being immunologic "hot," "cold," or "excluded" can offer a forecast of patients' prognosis and may thus aid as a potential prognostic tool in routine pathology reports. This "hot-cold-excluded" scheme needs to be applied to more HNSCC cohorts and possibly to other cancer types to determine prognostic meaning, e.g., regarding OS or DFS. Furthermore, our cohort reflects epidemiological data in the national, European, and international context. It may, therefore, be of use for future HNSCC characterization.
Background: Head and neck squamous cell carcinoma (HNSCC) represents a common cancer worldwide. Past therapeutic advances have not significantly improved HNSCC prognosis. Therefore, it is necessary to further stratify HNSCC, especially with recent advances in tumor immunology. Methods: Tissue microarrays were assembled from tumor tissue samples and were complemented with comprehensive clinicopathological data of n = 419 patients. H&E whole slides from resection specimen (n = 289) were categorized according to their immune cell infiltrate as "hot," "cold," or "excluded." Results: Investigating tumor immune cell patterns, we found significant differences in survival rates. Immunologic "hot" and "excluded" HNSCCs are associated with better overall survival than "cold" HNSCC patients (p < 0.05). Interestingly, the percentage of all three patterns is nearly identical in p16 positive and negative HNSCCs. Conclusions: Using a plain histological H&E approach to categorize HNSCC as being immunologic "hot," "cold," or "excluded" can offer a forecast of patients' prognosis and may thus aid as a potential prognostic tool in routine pathology reports. This "hot-cold-excluded" scheme needs to be applied to more HNSCC cohorts and possibly to other cancer types to determine prognostic meaning, e.g., regarding OS or DFS. Furthermore, our cohort reflects epidemiological data in the national, European, and international context. It may, therefore, be of use for future HNSCC characterization.
Authors: I Tinhofer; K Jöhrens; U Keilholz; A Kaufmann; A Lehmann; W Weichert; A Stenzinger; C Stromberger; K Klinghammer; E-T Becker; S Dommerich; K Stölzel; V M Hofmann; B Hildebrandt; L Moser; J Ervens; A Böttcher; A Albers; R Stabenow; A Reinecke; V Budach; B Hoffmeister; J D Raguse Journal: Eur J Cancer Date: 2015-01-23 Impact factor: 9.162
Authors: Lisa M McShane; Douglas G Altman; Willi Sauerbrei; Sheila E Taube; Massimo Gion; Gary M Clark Journal: J Natl Cancer Inst Date: 2005-08-17 Impact factor: 13.506
Authors: Elgar Susanne Quabius; Jochen Haag; André Kühnel; Hannes Henry; Anna Sophie Hoffmann; Tibor Görögh; Jürgen Hedderich; Matthias Evert; Achim G Beule; Steffen Maune; Rainald Knecht; Attila Óvári; Martin Durisin; Florian Hoppe; Silke Tribius; Christoph Röcken; Petra Ambrosch; Markus Hoffmann Journal: Int J Oncol Date: 2014-10-07 Impact factor: 5.650
Authors: Maria Vassilakopoulou; Margaritis Avgeris; Vamsidhar Velcheti; Vassiliki Kotoula; Theodore Rampias; Kyriakos Chatzopoulos; Christos Perisanidis; Christos K Kontos; Aris I Giotakis; Andreas Scorilas; David Rimm; Clarence Sasaki; George Fountzilas; Amanda Psyrri Journal: Clin Cancer Res Date: 2015-09-25 Impact factor: 12.531
Authors: T J Ervin; J R Clark; R R Weichselbaum; B G Fallon; D Miller; R L Fabian; M R Posner; C M Norris; S A Tuttle; D A Schoenfeld Journal: J Clin Oncol Date: 1987-01 Impact factor: 44.544
Authors: Jared M Newton; Aurelie Hanoteau; Hsuan-Chen Liu; Angelina Gaspero; Falguni Parikh; Robyn D Gartrell-Corrado; Thomas D Hart; Damya Laoui; Jo A Van Ginderachter; Neeraja Dharmaraj; William C Spanos; Yvonne Saenger; Simon Young; Andrew G Sikora Journal: J Immunother Cancer Date: 2019-08-13 Impact factor: 13.751
Authors: Luise Klapper; Christian Idel; Patrick Kuppler; Tobias Jagomast; Amelie von Bernuth; Karl-Ludwig Bruchhage; Dirk Rades; Anne Offermann; Jutta Kirfel; Sven Perner; Julika Ribbat-Idel Journal: J Pers Med Date: 2022-06-17
Authors: T Jagomast; C Idel; L Klapper; P Kuppler; L Proppe; S Beume; M Falougy; D Steller; S G Hakim; A Offermann; M C Roesch; K L Bruchhage; S Perner; J Ribbat-Idel Journal: Histol Histopathol Date: 2022-02-11 Impact factor: 2.130
Authors: Julika Ribbat-Idel; Franz F Dressler; Rosemarie Krupar; Christian Watermann; Finn-Ole Paulsen; Patrick Kuppler; Luise Klapper; Anne Offermann; Barbara Wollenberg; Dirk Rades; Simon Laban; Markus Reischl; Karl-Ludwig Bruchhage; Christian Idel; Sven Perner Journal: Front Med (Lausanne) Date: 2021-04-27
Authors: Christian Idel; Julika Ribbat-Idel; Luise Klapper; Rosemarie Krupar; Karl-Ludwig Bruchhage; Eva Dreyer; Dirk Rades; Christina Polasky; Anne Offermann; Jutta Kirfel; Sven Perner; Barbara Wollenberg Journal: Front Oncol Date: 2021-10-28 Impact factor: 6.244